Using almost the same cohort, in 414 BRCA1/2mut cancers, Jorgensen et al. [123] examined other immune markers and observed a 26% reduction in risk of disease-free survival for a 10% increase in CD8-positive cells, with a similar trend seen for CD4 and FOXP3 expression, the latter most prominently in BRCA1mut-associated tumours. This evidence concerns the gene FOXP3 and neoplasm.